Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma
Here, we report on a phase IIa study to determine the intubation rate, survival, viral clearance, and development of endogenous Abs in patients with COVID-19 pneumonia treated with convalescent plasma (CCP) containing high levels of neutralizing anti–SARS-CoV-2 Abs. Radiographic and laboratory evalu...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Clinical investigation
2021-03-01
|
| Series: | JCI Insight |
| Subjects: | |
| Online Access: | https://doi.org/10.1172/jci.insight.143196 |
| _version_ | 1818723223601152000 |
|---|---|
| author | Michele L. Donato Steven Park Melissa Baker Robert Korngold Alison Morawski Xue Geng Ming Tan Andrew Ip Stuart Goldberg Scott Rowley Kar Chow Emily Brown Joshua Zenreich Phyllis McKiernan Kathryn Buttner Anna Ullrich Laura Long Rena Feinman Andrea Ricourt Marlo Kemp Mariefel Vendivil Hyung Suh Bindu Balani Cristina Cicogna Rani Sebti Abdulla Al-Khan Steven Sperber Samit Desai Stacey Fanning Danit Arad Ronaldo Go Elizabeth Tam Keith Rose Sean Sadikot David Siegel Martin Gutierrez Tatyana Feldman Andre Goy Andrew Pecora Noa Biran Lori Leslie Alfred Gillio Sarah Timmapuri Michele Boonstra Sam Singer Sukhdeep Kaur Ernest Richards David S. Perlin |
| author_facet | Michele L. Donato Steven Park Melissa Baker Robert Korngold Alison Morawski Xue Geng Ming Tan Andrew Ip Stuart Goldberg Scott Rowley Kar Chow Emily Brown Joshua Zenreich Phyllis McKiernan Kathryn Buttner Anna Ullrich Laura Long Rena Feinman Andrea Ricourt Marlo Kemp Mariefel Vendivil Hyung Suh Bindu Balani Cristina Cicogna Rani Sebti Abdulla Al-Khan Steven Sperber Samit Desai Stacey Fanning Danit Arad Ronaldo Go Elizabeth Tam Keith Rose Sean Sadikot David Siegel Martin Gutierrez Tatyana Feldman Andre Goy Andrew Pecora Noa Biran Lori Leslie Alfred Gillio Sarah Timmapuri Michele Boonstra Sam Singer Sukhdeep Kaur Ernest Richards David S. Perlin |
| author_sort | Michele L. Donato |
| collection | DOAJ |
| description | Here, we report on a phase IIa study to determine the intubation rate, survival, viral clearance, and development of endogenous Abs in patients with COVID-19 pneumonia treated with convalescent plasma (CCP) containing high levels of neutralizing anti–SARS-CoV-2 Abs. Radiographic and laboratory evaluation confirmed all 51 treated patients had COVID-19 pneumonia. Fresh or frozen CCP from donors with high titers of neutralizing Abs was administered. The nonmechanically ventilated patients (n = 36) had an intubation rate of 13.9% and a 30-day survival rate of 88.9%, and the overall survival rate for a comparative group based on network data was 72.5% (1625/2241). Patients had negative nasopharyngeal swab rates of 43.8% and 73.0% on days 10 and 30, respectively. Patients mechanically ventilated had a day-30 mortality rate of 46.7%; the mortality rate for a comparative group based on network data was 71.0% (369/520). All evaluable patients were found to have neutralizing Abs on day 3 (n = 47), and all but 1 patient had Abs on days 30 and 60. The only adverse event was a mild rash. In this study on patients with COVID-19 disease, we show therapeutic use of CCP was safe and conferred transfer of Abs, while preserving endogenous immune response. |
| first_indexed | 2024-12-17T21:07:06Z |
| format | Article |
| id | doaj.art-4105869b8be542f7861f13287a3a1652 |
| institution | Directory Open Access Journal |
| issn | 2379-3708 |
| language | English |
| last_indexed | 2024-12-17T21:07:06Z |
| publishDate | 2021-03-01 |
| publisher | American Society for Clinical investigation |
| record_format | Article |
| series | JCI Insight |
| spelling | doaj.art-4105869b8be542f7861f13287a3a16522022-12-21T21:32:32ZengAmerican Society for Clinical investigationJCI Insight2379-37082021-03-0166Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasmaMichele L. DonatoSteven ParkMelissa BakerRobert KorngoldAlison MorawskiXue GengMing TanAndrew IpStuart GoldbergScott RowleyKar ChowEmily BrownJoshua ZenreichPhyllis McKiernanKathryn ButtnerAnna UllrichLaura LongRena FeinmanAndrea RicourtMarlo KempMariefel VendivilHyung SuhBindu BalaniCristina CicognaRani SebtiAbdulla Al-KhanSteven SperberSamit DesaiStacey FanningDanit AradRonaldo GoElizabeth TamKeith RoseSean SadikotDavid SiegelMartin GutierrezTatyana FeldmanAndre GoyAndrew PecoraNoa BiranLori LeslieAlfred GillioSarah TimmapuriMichele BoonstraSam SingerSukhdeep KaurErnest RichardsDavid S. PerlinHere, we report on a phase IIa study to determine the intubation rate, survival, viral clearance, and development of endogenous Abs in patients with COVID-19 pneumonia treated with convalescent plasma (CCP) containing high levels of neutralizing anti–SARS-CoV-2 Abs. Radiographic and laboratory evaluation confirmed all 51 treated patients had COVID-19 pneumonia. Fresh or frozen CCP from donors with high titers of neutralizing Abs was administered. The nonmechanically ventilated patients (n = 36) had an intubation rate of 13.9% and a 30-day survival rate of 88.9%, and the overall survival rate for a comparative group based on network data was 72.5% (1625/2241). Patients had negative nasopharyngeal swab rates of 43.8% and 73.0% on days 10 and 30, respectively. Patients mechanically ventilated had a day-30 mortality rate of 46.7%; the mortality rate for a comparative group based on network data was 71.0% (369/520). All evaluable patients were found to have neutralizing Abs on day 3 (n = 47), and all but 1 patient had Abs on days 30 and 60. The only adverse event was a mild rash. In this study on patients with COVID-19 disease, we show therapeutic use of CCP was safe and conferred transfer of Abs, while preserving endogenous immune response.https://doi.org/10.1172/jci.insight.143196COVID-19 |
| spellingShingle | Michele L. Donato Steven Park Melissa Baker Robert Korngold Alison Morawski Xue Geng Ming Tan Andrew Ip Stuart Goldberg Scott Rowley Kar Chow Emily Brown Joshua Zenreich Phyllis McKiernan Kathryn Buttner Anna Ullrich Laura Long Rena Feinman Andrea Ricourt Marlo Kemp Mariefel Vendivil Hyung Suh Bindu Balani Cristina Cicogna Rani Sebti Abdulla Al-Khan Steven Sperber Samit Desai Stacey Fanning Danit Arad Ronaldo Go Elizabeth Tam Keith Rose Sean Sadikot David Siegel Martin Gutierrez Tatyana Feldman Andre Goy Andrew Pecora Noa Biran Lori Leslie Alfred Gillio Sarah Timmapuri Michele Boonstra Sam Singer Sukhdeep Kaur Ernest Richards David S. Perlin Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma JCI Insight COVID-19 |
| title | Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma |
| title_full | Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma |
| title_fullStr | Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma |
| title_full_unstemmed | Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma |
| title_short | Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma |
| title_sort | clinical and laboratory evaluation of patients with sars cov 2 pneumonia treated with high titer convalescent plasma |
| topic | COVID-19 |
| url | https://doi.org/10.1172/jci.insight.143196 |
| work_keys_str_mv | AT micheleldonato clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT stevenpark clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT melissabaker clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT robertkorngold clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT alisonmorawski clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT xuegeng clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT mingtan clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT andrewip clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT stuartgoldberg clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT scottrowley clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT karchow clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT emilybrown clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT joshuazenreich clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT phyllismckiernan clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT kathrynbuttner clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT annaullrich clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT lauralong clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT renafeinman clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT andrearicourt clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT marlokemp clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT mariefelvendivil clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT hyungsuh clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT bindubalani clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT cristinacicogna clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT ranisebti clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT abdullaalkhan clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT stevensperber clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT samitdesai clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT staceyfanning clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT danitarad clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT ronaldogo clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT elizabethtam clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT keithrose clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT seansadikot clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT davidsiegel clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT martingutierrez clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT tatyanafeldman clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT andregoy clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT andrewpecora clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT noabiran clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT lorileslie clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT alfredgillio clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT sarahtimmapuri clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT micheleboonstra clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT samsinger clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT sukhdeepkaur clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT ernestrichards clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma AT davidsperlin clinicalandlaboratoryevaluationofpatientswithsarscov2pneumoniatreatedwithhightiterconvalescentplasma |